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Sanitari del Maresme, Mataro´, Barcelona, SpainObjective. To assess the efficacy and safety of sclerotherapy performed with polidocanol foam compared to liquid
polidocanol.
Methods. Controlled clinical trial with 1 year follow up in which each patient acted as his/her own control. A total of 75
patients (six men and 69 women) with reticular or postoperative varices were enrolled and sclerotherapy was performed with
liquid and with foam (Tessari method) using the same quantity of sclerosant for homogeneous varicose regions, to a total of
150 procedures. The sclerosant concentration was adjusted according to the vein diameter as assess by ultrasonography. The
foam group was given 50% lower concentrations of sclerosant than liquid sclerosant group. Clinical assessment (pain,
inflammation, pigmentation) and ultrasound examination (diameter of the lumen and length of sclerosed vein) were carried
out at 15, 30, 90, and 365 days.
Results. Foam allowed complete sclerosis at 90 days in 94.4% of patients compared with 53% for liquid (p!.001) and also
allowed a more extensive venous sclerosis (10.1 cm compared with 7.2 cm; p!.001). Pain, signs of inflammation, and
pigmentation appeared more often with foam sclerosis, with significant difference. The degree of satisfaction was similar for
both techniques.
Conclusions. Efficacy of venous sclerosis with foam seems to be greater than with liquid although there is a higher risk of
minor secondary effects.Keywords: Varicose veins; Sclerotherapy; Foam polidocanol; Efficacy; Skin pigmentation; Local inflammatory signs.Introduction
In 1944 Orbach1 introduced the air block method, to
displacing the column of blood with air. He later
developed a foam by shaking sodium tetradecylsul-
phate to create a froth and reported that this was more
effective than the same sclerosant used as a liquid.
Fifty years went by before Cabrera2 developed a
microfoam (comprising very small bubbles) by mixing
polidocanol with gas under high pressure (CO2/O2/
N2). Subsequently several methods of producing
‘home made’ foam were developed: Monfreux3 by
moving a plug in a glass syringe, Benigni4 who used a
disposable syringe, Garcı´a-Mingo5 who mixed the
sclerosant with compressed air, Tessari6 who used two
syringes connected by a three-way stopcock which
mixed the sclerosant with atmospheric air, anding author. Dr Jesu´s Alo´s Villacrosa, Servicio de
Cirugı´a Vascular, Hospital de Mataro´, Crta. Cirera
ataro´, Barcelona, Spain.
: 14545jav@comb.es
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The principal advantage of home made foam is that it
can be readily created using commonly available
supplies for immediate use. This is currently the
only way that sclerosant foam may be obtained. Some
authors have indicated that commercial systems
produce foam of better quality,9 although there is no
proof today that these give better results.
Despite these developments the appropriate
strength and volume of sclerosant foam to use in
different sizes and types of vein has yet to be
established. Tables with suggested concentrations of
several sclerosants, principally polidocanol and
sodium tetradecylsulphate, for saphenous trunks,
perforators, and collaterals of varying sizes, have
been published recently based on the clinical experi-
ence of the authors.10 Likewise, although the efficacy
of foam seems evident, results from the various studies
differ over the frequency and severity of common
complications of treatment (inflammatory signs, pain,
pigmentation, etc.). The safety of foam treatmentEur J Vasc Endovasc Surg 31, 101–107 (2006)
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J. Alo`s et al.102and its relation to the concentrations of sclerosant used
are still uncertain. The objective of this study is to
assess the efficacy of the sclerosant polidocanol in
foam form compared to the liquid form at pre-
established concentrations, and to determine the
safety profile by measuring the frequency and degree
of short, medium, and long term post-sclerosis
complications.Table 1. Concentrations of polidocanol according to the diameter
of the varices and quantities used per injection
Dia´meter Lı´quid Foam
1–2 mm 1% 0.5%
2.1–3 mm 1.25% 0.65%
3.1–4 mm 1.5% 0.75%
4.1–5 mm 2% 1%
5.1–6 mm 2.5% 1.25%
Volume per injection 0.5 mL 2 mL
Quantity (polidocanol) per injection 0.5 mL 0.5 mLMaterial and Methods
A double-blind, controlled clinical trial was designed
in which each patient acting as his or her own control.
Each patient received both study sclerosants (polido-
canol foam and liquid polidocanol) in different
locations containing similar varices. Both the patient
and the research assistant who assessed the clinical
and ultrasound results were blind to the type of
treatment applied in each area. The study population
consisted of men and women with symptomatic
varicose veins and the study sample was enrolled at
the outpatient clinic of the Department of Angiology
and Vascular Surgery of a general hospital.
Patients were preselected in the outpatient clinic by
a detailed clinical examination. Patients with primary
reticular varices (those of more than 2 mm of
diameter) or postoperative varices in more than one
region that did not involve the saphenofemoral
junction were included in the study. The varices
treated were of similar size and within pre-established
groups in different limbs for bilaterally affected
patients or different regions of the same limb for
unilaterally affected patients. The following patients
were excluded from the study: patients with truncal
varices with junctional (terminal valve) and extra-
junctional incompetence, postoperative varices that
involved the saphenofemoral junction, post-thrombo-
tic varices with occluded deep veins, varices second-
ary to arteriovenous fistulas, bilateral varices of
asymmetric calibre, unilateral varices with asym-
metric calibre between regions, chronic ischemia of
the lower limbs, severe arterial hypertension (blood
pressure greater than 180/95 mmHg), and patients
being treated with anticoagulants and anti-inflamma-
tories and/or diuretics for other pathologies to avoid
these affecting the appearance or degree of possible
secondary effects. From the beginning of the field
study, all patients who fulfilled the selection criteria
were invited to participate. Six patients that were
initially pre-selected were finally excluded for meeting
some exclusion criteria. The Ethics Committee of the
hospital assessed and approved the protocol ofEur J Vasc Endovasc Surg Vol 31, 1 2006the study. All patients gave informed written consent
before inclusion.
Patients included in the study underwent venous
colour duplex ultrasonography while standing includ-
ing ultrasound measurement of the mean diameter of
the varices. The length of the vein to be treated was
determined using a simple tape measure. A graph was
made to identify the anatomical region to be treated
and to record the region treated with each procedure.
Skin pigmentation was recorded using Fitzpatrick
phototypes.
All patients underwent one session of sclerotherapy
in which both sclerosants (foam and liquid polidoca-
nol) were given. Patients received the sclerotherapy in
both regions by the same doctor, whether in different
limbs or the same limb in different regions. Regions
were randomly assigned one or other procedure as
follows; the right limb (if both legs were involved) or
the upper region (if only one leg was involved) were
always treated first. The assignment of the first region
to be treated to liquid or foam was performed
according to a list of 38 random numbers from 0 to
75 created by an specific software. Each patient had an
identification number according strict chronological
recruitment order, if this number was in the list of
random numbers then the patient received first foam
and if not received liquid sclerosant first.
The intervention in the study group consisted of
injecting 2 mL of foam into only one varicose vein. The
concentration depended on the diameter of the vein
measured with Duplex ultrasound with the patient
standing. The quantities and concentrations used were
established before this study commenced from our
clinical practice and are presented in Table 1. Foam
was obtained from 0.5 mL of liquid polidocanol mixed
with air at a ratio of 1:4, using the Tessari method
which uses a three-way stopcock to mix the sclerosant.
So 2 mL of foam contained 0.5 mL of polidocanol.
After the sclerosant was injected, the sclerosed vein
was compressed for 48 h with stockings at a pressure
of 25–35 mmHg, while patients resumed a normal life
style and regularly applied heparinoid ointment (three
times a day). After the sclerosant injection, any pain,
Sclerotherapy with Polidocanol Foam 103dizziness, blurred vision, or other complication that
could be related to the injection were recorded. The
intervention in the control group consisted of a 0.5 mL
liquid polidocanol injection in only one varicose vein
in the corresponding region. An antegrade injection
technique was used with the same kind of material (a
2 mL syringe and a 25 g, 5/8 needle) and the same
postoperative care regarding compression and hepar-
inoid as the study group. The same quantity of
sclerosant (0.5 mL polidocanol), at the concentration
stipulated in Table 1, was used in each injection in the
foam and liquid sclerosant groups.
Efficacy was assessed according to whether scler-
osis of the vein was complete as shown by duplex
ultrasound performed by an observer unaware of the
treatment group assigned to each area of the limb.
Sclerosis was considered complete when the lumen ofAssessment for
elegibility (n=81)
Patients included (n=7
Varices to be treated
(2 for each patient)(n=
Varices treated with foam
(n=75)
Varices lost to follow-up
15 th day (n=0)
30 th day (n=1)
90 th day (n=4)
365 th day (n=12)
Varices analysed
15 th day (n=75)
30 th day (n=74)
90 th day (n=71)
365 th day (n=63)
randomisation
Fig. 1. Flow diagrthe vein was sealed and the vein occluded. Total
efficacy corresponded to complete sclerosis and partial
efficacy to incomplete sclerosis when obliteration of
the lumen was less than 100%. The length of the
sclerosed vein, measured in cm with a tape measure,
was also assessed. Appearance of the following side
effects was recorded: pain in the treated region graded
on an ordinal scale (absent, mild, moderate, or severe),
requirement for analgesic treatment and type of
analgesic given, inflammation in the treated region
and degree of severity of inflammation (mild, moder-
ate, severe) according to clinical criteria, appearance of
skin pigmentation in the sclerosis region, formation of
bulla, cutaneous necrosis and other effects. Efficacy
was assessed at 15, 30, and 90 days after the
sclerotherapy and safety was evaluated at 15, 30, 90,
and 365 days. Overall patient satisfaction with each5)
150)
Excluded (n=6)
Not meeting selection criteria (n=6)
Refused (n=0)
Varices treated with liquid
(n=75)
Varices lost to follow-up
15 th day (n=1)
30 th day (n=1)
90 th day (n=4)
365 th day (n=12)
Varices analysed
15 th day (n=74)
30 th day (n=74)
90 th day (n=71)
365 th day (n=63)
am of the trial.
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Table 2. Assessment of efficacy according to degree of occlusion
and length of treated vein
Control Efficacy Lı´quid Foam p
Day 15 Total 47% 88% !0.001
Partial 46% 12% !0.001
Length 7.2 cm 9.3 cm 0.121
Day 30 Total 54% 93% !0.001
Partial 38% 6.8% !0.001
Length 7.3 cm 10 cm 0.088
J. Alo`s et al.104technique was also assessed at the final follow-up
appointment using a visual analogue scale (VAS) from
0 (minimum satisfaction) to 10 (maximum satisfac-
tion), directly responded by the patient. Results were
assessed by a member of the research team other than
the doctor who had performed the treatment. Fig. 1
shows a flow diagram of the progress of the trial
through its different phases.Day 90 Total 54% 94% !0.001
Partial 35% 5.6% !0.001
Length 7.2 cm 10 cm 0.038Statistics
Assuming an alpha error of 0.05, a statistical power of
90% and an estimated efficacy (complete sclerosis) of
95% for one group and 80% for the other, a minimum
of 70 patients per group was considered necessary. To
account for possible follow-up losses, the sample size
was established at 75 patients per group.
The McNemar test was used to compare the
proportions between the two intervention groups,
and the paired Student t test was used to assess within
group differences. The chi-squared test was used to
compare proportions between independent samples.
To adjust the effect of the type of intervention (foam or
liquid), for type of skin (white or otherwise) in the
appearance of skin pigmentation, a multivariate
logistic regression model was used. In all cases a p
value !.05 was considered significant.Table 3. Presentation of pain and use of post-sclerosis analgesics
Control Parameter Liquid (%) Foam (%) pResults
The sample consisted of 75 patients, 69 women (92%)
and 6 men (8%), with a mean age of 59 years (range:
23–78), on whom 150 sclerosis procedures were
performed, 104 (69%) being postoperative varices
and 46 (31%) reticular varices. In no cases an
incompetent perforator was present. Of the 75 original
patients, four had left the study by the 90-day follow-
up interval and 12 by the 365-day assessment.Day 15 Pain
Absent 73 36
Mild 20 39
Moderate 6.8 21
Severe 0 4.0 !0.001
Analgesic use 6.8 16 0.12
Day 30 Pain
Absent 92 64
Mild 8.1 27
Moderate 0 9.5
Severe 0 0 !0.001
Analgesic use 1.4 12 0.017
Day 90 Pain
Absent 99 92
Mild 1.4 8.5 0.116
Moderate 0 0
Severe 0 0
Analgesic use 0 0 –Efficacy
Three months after treatment, total occlusion of the
vein was observed in 94% of foam interventions and
54% of liquid interventions (p!.001). Differences in
the percentages of total efficacy for the two study
groups were statistically significant at 15 days and at
30 days after the operation. At the 90-day control, the
length of the sclerosed vein was also greater for the
foam group with respect to the control group (10.1 cm
compared with 7.2 cm, respectively, p!.0001)
although this difference was not significant at
15 days and 30 days (Table 2).Eur J Vasc Endovasc Surg Vol 31, 1 2006Complications of treatment
No complication occurred at the time of sclerotherapy
(pain, dizziness, blurred vision, and other effects) in
either of the treatment groups. Table 3 shows that pain
localised in the sclerosis region at the 15- and 30-day
examinations occurred more often in the foam group
was more severe. Analgesics were more often required
by the foam group, paracetamol being the most used
(16% of all cases), followed by diclofenac (4% of all
cases) and acetylsalicylic acid and metamizole (1.4% of
all cases). Local inflammation at 15 days was present
in 25.3% of the foam group and 9.5% of the controls
(pZ.077). Inflammatory signs had disappeared in the
control group but persisted in 9.5% of the study group
at 30 days and in 1.4% at 90 days. Table 4 shows that
the percentage of pigmentation in the treated regions
after sclerotherapy was significantly higher at all
follow-up intervals for the foam group, maximum
levels being reached for both groups at 90 days and
subsequently decreasing at the final examination.
Assessing the appearance of pigmentation compared
to the patients’ skin phototype revealed that
Table 5. Percentage of pigmentation according to skin phototype
Control Phototype p
1–2 (%) 3–4 (%) 5–6 (%)
Day 90 61 26 32 0.01
Day 365 39 14 30 0.02
Table 4. Percentage of pigmentation for both groups
Control Lı´quid (%) Foam (%) p
Day 15 15 47 !0.0001
Day 30 15 53 !0.0001
Day 90 13 49 !0.0001
Day 365 6.3 33 !0.0001
Sclerotherapy with Polidocanol Foam 105Fitzpatrick phototypes 1 and 2 (white skin) were more
susceptible to post-sclerosis pigmentation (Table 5).
When the effect of type of intervention (foam or liquid)
was adjusted for skin type (white or other) in a logistic
regression model, both variables were seen to have a
significant effect on the appearance of pigmentation at
90 days with odds ratios of 8.1 (p!.0001) and 6.4
(pZ.003), respectively. This effect persisted at 365 days
with an odds ratio of 8.1 (p!.001) for foam treatment
and an odds ratio of 4.0 (pZ.026) for white skin type.
Differences between risks of pigmentation related to
concentrations used were not found (Fig. 2).Satisfaction
Patient satisfaction with each of the treatments
received was assessed at the 365-day control on a
numerical scale from 0 to 10. Mean score for the liquid
sclerosis group was 7.2 (SD 1.5) and for the foam
sclerosis group was 7.4 (SD 1.2). The difference was not
significant.0
10
20
30
40
50
60
0.65% 0.75% 1% 1.25%
YES
NO
Fig. 2. Percentage of pigmentation related to concentrations
in the foam group.Discussion
The results of this study show that for the same
concentration of polidocanol, the efficacy of scler-
otherapy with foam is greater than with liquid,
although risks of minor adverse effects such as pain,
inflammation, and skin pigmentation are also more
frequent. Other authors have published similar results
when using duplex-guided sclerotherapy.11,12 The
specific characteristics of foam sclerosants may explain
their greater capacity and irritant nature. Foam
sclerosants are compact solutions that displace the
blood column rather than dissolving in the circulating
blood. Foam adheres better to the walls of the vein, a
feature that, together with the capacity to provoke
spasm, allows greater contact with the endothelium,
conferring greater efficacy at lower concentrations and
lower total quantity of sclerosant.13 The durability of
the foam sclerosant combined with a greater capacity
to penetrate collaterals results in sclerosis over a larger
region. The foam is highly echogenic which facilitates
ultrasound guided sclerotherapy, increasing the safety
of sclerosis of saphenous axes.14,15 The greater efficacy
seen in the foam group confirms the advantages of this
type of sclerosis and confirmation of efficacy by
Duplex ultrasound added value to the study. From
the practical point of view, foam sclerosis involves
cheap, readily available, and easy to use products in
daily practice, not unduly lengthening the medical
process and probably reducing the number of sessions
needed to treat each patient.
Regarding the safety of the treatment, Harkins and
Harmon16 in 1934 and Richardson17 in 1937 demon-
strated the safety of injecting animals with small doses
of endovenous air for short periods. Based on these
experiments, Henriet18 analyzed the passage of this air
to the circulation system under several conditions of
extracorporeal circulation or during echocardiograms
using air, confirming the safety of the procedure. These
results are consistent with several later clinical studies
using foam produced by various techniques19,20
proving that small doses of air injected intravenously
do not produce major systemic changes and are well
tolerated by patients. The presentation of major
complications (deep vein thrombosis or lung throm-
boembolism) is unusual with this technique and is
probably related to the dose used and the sclerosis
region, occurring considerably more often with truncal
saphenous sclerosis, incompetent perforator veins,
and when large doses of foam are used.21 None of
these complications occurred in our study or in similar
studies, mainly due to the type of veins treated
(reticular and postoperative) and the low doses and
concentrations used. The minor complicationsEur J Vasc Endovasc Surg Vol 31, 1 2006
J. Alo`s et al.106recorded (local inflammation and hyperpigmenta-
tion), which in our study were very similar to the
study published by Benigni and Sadoun,4 present
widely divergent percentages in the literature, attribu-
table to several possible factors: the method of foam
production, as non-industrial methods do not produce
a completely standardised microfoam; and the rela-
tively low concentrations and quantities used in each
session (higher concentrations of sclerosant produce
smaller size bubbles). The larger bubble size could be
directly related to the appearance of inflammation
beyond the endothelium, involving the whole venous
wall and the perivenous tissue with the consequent
clinical signs and anti-aesthetic secondary effects such
as skin pigmentation.22 However, there is a clear
tendency towards the reduction of foam concen-
trations in order to achieve better results and avoid
the secondary effects characteristic of this technique.
These concentrations are between 25 and 30% lower
than those used in this study.10 The use of post-
sclerosis, elastic compression for only 48 h could have
been another possible influential factor as longer term
compression has been shown to be effective in
reducing inflammation and its consequences.23 Skin
pigmentation can also be reduced by performing
drainage micro-thrombectomy on the thrombosis of
the treated vein.24 Other minor complications that
have been described in the literature (dizziness and
blurred vision) derive from the passing of air from the
foam to the circulation system, are related to the total
quantity of injected foam, and are prevented by the
patient gradually sitting up and previous elevation of
the treated limb.25 No incident of this kind was
recorded in our study due probably to the low doses
administrated to all patients. Neither was a significant
relation found between presentation of pigmentation
and the concentration of sclerosant used, but the
sample size was small and statistical power limited, so
care must be used in the interpretation of this result.
On the other hand, phototypes 1 and 2 of Fitzpatrick
skin classification have shown a greater risk of
pigmentation, which should be take into account
when using sclerotherapy, specially in foam form.
An important feature of the design of this study and
one which made the two groups more homogeneous
and easier to compare, was use of the two techniques
simultaneously on the same patient, each of whom
acted as his/her own control. Assessment of the
differences between the procedures was thus, more
valid and precise with regard to both efficacy and
complications as any possible confounding factors that
depended on the patients were automatically cor-
rected and variability was greatly reduced. Likewise,
the use of the duplex ultrasound allowed for greaterEur J Vasc Endovasc Surg Vol 31, 1 2006accuracy and objectivity in determining the percen-
tages of sclerosant for each venous calibre and enabled
accurate measurement of partial and complete efficacy.
In conclusion, the results of this study demonstrate
that foam polidocanol has greater sclerosant efficacy
compared to liquid polidocanol in the treatment of
reticular and postoperative varices not involving the
saphenofemoral junction. A larger percentage of total
sclerosis as well as the extent of the obliterated region
was observed. Despite this, foam sclerosant also
showed a greater tendency to provoke inflammation
and consequently mild adverse effects including pain,
signs of inflammation and skin pigmentation. Foam
sclerotherapy should be considered the treatment of
first choice in symptomatic patients with varicose
veins provided that patients are aware that some long
lasting pigmentation may result.References
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